

FORM PTO 1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 99-16C1

Serial No.
10/659,684

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant(s):

Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond

Filing Date: September 10, 2003 Group: 1644
1647

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|-----|-----------------|----------|-------------------|-------|----------|----------------------------|
| JS | A1 | 10/456,262 | 06-06-03 | Nelson et al. | | | |
| | A2 | 11/285,970 | 11/23/05 | Yee | | | |
| | A3 | 11/346,580 | 02-02-06 | Novak et al. | | | |
| | A4 | 2004-0009150 | 01-15-04 | Nelson et al. | | | |
| | A5 | 2004-0260065 | 12/23/04 | Novak et al. | | | |
| | A6 | 2005-0095223 | 05-05-05 | Sivakumar et al. | | | |
| | A7 | 2005-0244930 | 11/03/05 | Presnell et al. | | | |
| | A8 | 2005-0265966 | 12-01-05 | Kindsvogel et al. | | | |
| | A9 | 2006-0134754 | 06/22/06 | Chan et al. | | | |
| | A10 | 6,307,024 | 10/23/01 | Parrish et al. | | | |
| | A11 | 6,605,272 | 08/12/03 | Dillon et al. | | | |
| ↓ | A12 | 6,686,178 | 02-03-04 | Dillon et al. | | | |
| | A13 | 6,929,932 | 08/16/05 | Presnell et al. | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|-----|-----------------|----------|---------|-------|----------|----------------------------|
| JS | A14 | 03/103589 | 12/18/03 | WO | | | |
| | A15 | 04/032857 | 04/22/04 | WO | | | |
| | A16 | 05/037306 | 04/28/05 | WO | | | |
| ↓ | A17 | 99/61617 | 12/02/99 | WO | | | |
| | A18 | 04/112703 | 12/29/04 | WO | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

| | | |
|----|-----|--|
| JS | A19 | Hill et al., "Cytokines: promoters and dampeners of autoimmunity," <i>Current Opinion in Immunology, Current Biology LTD</i> 14(6):791-797, 2002. |
| | | |
| | A20 | Clegg et al., "Therapeutic Opportunities for IL-21," <i>European Cytokine Network</i> vol. 14, no. Supplement 3, 2003. |
| | | |
| | A21 | Nelson, et al., "Interleukin 21 has anti-tumor activity in animal models without the toxicity of IL-2," <i>Procedures of the American Association for Cancer Research Annual Meeting</i> , vol. 44, July 2003. |
| | | |
| ↓ | A22 | Funaro et al., "Monoclonal antibodies and therapy of human cancers," <i>Biotechnology Advances</i> , Elsevier Publishing Barking, GB vol. 18 no. 5, 2000. |

| | |
|--|-----------------------------------|
| Examiner /Jegatheesan Seharaseyoon/ | Date considered 10/02/2006 |
|--|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.